CAR-T manufacturing reduces heterogeneity between CIDP and multiple myeloma patient-derived T cells.
CAR-T 细胞制造技术降低了 CIDP 和多发性骨髓瘤患者来源 T 细胞之间的异质性。
期刊:Theranostics
影响因子:13.3
doi:10.7150/thno.125983
Wang Xu, Wang Pu, Zhou Qi, Wei Xianzheng, Jin Yuhang, Liao Ying, Zhao Xuan, Hou Rui, Li Sijin, Guan Zhangchun, Ma Wen, Liu Dan, Shi Ming